Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.

Long-acting somatostatin analogs are frequently used as adjuvant treatment of acromegaly patients after noncurative surgery.

Evaluations included insulin-like growth factor I (IGF-I) and growth hormone (GH) after oral glucose tolerance test (OGTT) 3, 6, 12 and 18 months after starting medical treatment; pituitary magnetic resonance imaging was performed before treatment and after 3 and 12 months.

Who Took Part

According to the abstract, 25 men were involved.

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

The patients were assigned randomly to OCT (n = 36) and LAN (n = 32) groups.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Evaluations included insulin-like growth factor I (IGF-I) and growth hormone (GH) after oral glucose tolerance test (OGTT) 3, 6, 12 and 18 months after starting medical treatment; pituitary magnetic resonance imaging was performed before treatment and after 3 and 12 months.

The subject headings attached to it are Acromegaly, Glucose Tolerance Test, Human Growth Hormone, Hypophysectomy, Insulin-Like Growth Factor I, Octreotide and Peptides, Cyclic.

What This Means in Plain Language

The paper is a randomized study of Octreotide and Somatostatin in 25 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2012 (Pituitary), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.